{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Adenocarcinoma","Colorectal Adenocarcinoma","Colorectal cancer"],"disease":["Adenocarcinoma","Colorectal Adenocarcinoma","Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2121875"],"location":["China"],"study_start_month":["3"],"keyword":["XELOX","Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma","description":"This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and capecitabine on metastatic colorectal adenocarcinoma in the first-line therapy.","dates":{"creation":"2012-03-15"},"accession":"2121875","cross_references":{"ClinicalTrials___gov":["NCT01552967"]}}